Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Total Liabilities: 2019-2025

Historic Total Liabilities for Eton Pharmaceuticals (ETON) over the last 7 years, with Sep 2025 value amounting to $81.4 million.

  • Eton Pharmaceuticals' Total Liabilities rose 309.79% to $81.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $81.4 million, marking a year-over-year increase of 309.79%. This contributed to the annual value of $51.7 million for FY2024, which is 217.87% up from last year.
  • Latest data reveals that Eton Pharmaceuticals reported Total Liabilities of $81.4 million as of Q3 2025, which was up 4.72% from $77.7 million recorded in Q2 2025.
  • Eton Pharmaceuticals' Total Liabilities' 5-year high stood at $81.4 million during Q3 2025, with a 5-year trough of $9.2 million in Q2 2021.
  • For the 3-year period, Eton Pharmaceuticals' Total Liabilities averaged around $34.7 million, with its median value being $18.4 million (2024).
  • Per our database at Business Quant, Eton Pharmaceuticals' Total Liabilities fell by 7.70% in 2021 and then spiked by 323.26% in 2025.
  • Over the past 5 years, Eton Pharmaceuticals' Total Liabilities (Quarterly) stood at $9.8 million in 2021, then increased by 21.53% to $12.0 million in 2022, then surged by 36.07% to $16.3 million in 2023, then surged by 217.87% to $51.7 million in 2024, then soared by 309.79% to $81.4 million in 2025.
  • Its Total Liabilities stands at $81.4 million for Q3 2025, versus $77.7 million for Q2 2025 and $59.6 million for Q1 2025.